Stanford blood cancer transplant therapy reaches first commercial patient
Global - Asia
Archived
•
October 8, 2026
•
In a remarkable advancement, Stanford researchers have unveiled Orca-T therapy, which has recently received FDA approval. After two decades of rigorous development, this innovative treatment was administered to its inaugural commercial patient, a high-risk leukemia sufferer. Notably, Orca-T significantly minimizes the chances of graft-versus-host disease post-stem cell transplants, offering reduced chemotherapy requirements and lower side effects. Future studies are anticipated to investigate its relevance for broader patient demographics.
Source: Times of India | https://timesofindia.indiatimes.com/rssfeedstopstories.cms - Read Original
Discussion (0)
Please log in to post a comment.
No comments yet. Be the first to share your thoughts!



